Galmed Pharmaceuticals Ltd. filings document the company’s foreign private issuer reporting, Aramchol development disclosures and public-company governance matters. Recent Form 6-K reports furnish press releases on Aramchol-based collaborations, brain-penetrating formulation work, scientific presentations, Nasdaq minimum bid price correspondence and shareholder meeting materials.
The filing record also includes proxy and voting materials for special general meetings, incorporation of selected 6-K disclosures into Form S-8 and Form F-3 registration statements, and references to the company’s ordinary shares. These documents describe governance procedures, capital-market registration matters, listing-status communications and development updates for Galmed’s clinical-stage biopharmaceutical business.
Galmed Pharmaceuticals Ltd. is calling a Special General Meeting of Shareholders on March 4, 2026 in Ramat Gan, Israel. Holders of its ordinary shares as of the close of trading on February 12, 2026 are entitled to vote by proxy or in person.
The main proposal seeks shareholder approval of a framework for a reverse split of Galmed’s ordinary shares at a ratio between 1:2 and 1:250. The board of directors would be able to choose the exact ratio, number of increments and effective dates within 18 months after the meeting, and amend the amended and restated articles of association accordingly.
Galmed Pharmaceuticals Ltd. reported that it has received a notice from Nasdaq stating that its ordinary shares no longer meet the Nasdaq Capital Market’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). The company has 180 calendar days, from January 29, 2026 through July 28, 2026, to regain compliance. Galmed will be deemed compliant if its closing bid price is at least $1.00 for a minimum of ten consecutive business days within this period. If it does not regain compliance, it may qualify for an additional grace period if other listing standards are met, or its ordinary shares could ultimately be subject to delisting. The notice does not immediately affect the listing or trading of the shares, which continue on the Nasdaq Capital Market under the symbol GLMD.
Galmed Pharmaceuticals Ltd. filed a Form 6-K noting it issued a press release titled “Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting.” The update highlights that a late-breaking abstract involving the company will be presented at the HEP-DART 2025 Meeting.
The report specifies that this Form 6-K and the first two paragraphs of the attached press release are incorporated by reference into Galmed’s existing Registration Statements on Form S-8 and Form F-3, so this information now also forms part of those offerings.
Galmed Pharmaceuticals Ltd. (GLMD) reported unaudited Q3 2025 results and outlined a new digital asset treasury strategy. For the three months ended September 30, 2025, net loss was approximately $1.9 million, similar to Q3 2024, as higher research and development expenses of $1.1 million were offset by lower general and administrative costs of $1.0 million and higher financial income. For the nine months ended September 30, 2025, net loss increased to $5.5 million from $4.3 million, driven mainly by higher R&D spending and a $0.5 million impairment of the OnKai Inc. investment.
As of September 30, 2025, Galmed held $19.7 million in current assets, including $3.3 million in cash and cash equivalents, $7.6 million in short-term deposits and $8.2 million in marketable debt securities, and reported working capital of about $17.3 million. The company raised roughly $7.8 million in the first nine months of 2025 through an at-the-market sales agreement and a standby equity purchase agreement, increasing ordinary shares outstanding to 5,479,231.
Management believes existing funds will support current operations for more than 12 months, but significant additional capital will be needed to advance Aramchol, the Amilo-5MER program and other projects. In August 2025, the board approved a digital asset management strategy that contemplates allocating up to 50% of cash reserves into cryptocurrencies such as Bitcoin and Ethereum; no such allocation has yet been implemented.
Galmed Pharmaceuticals Ltd. submitted a report for foreign private issuers indicating that it furnished a press release dated November 18, 2025. The release is titled “Galmed Announces Meaningful Top Line Results from -001 Study of Aramchol Meglumine” and is attached as Exhibit 99.1.
Galmed Pharmaceuticals Ltd. filed a Form 6-K to furnish a press release announcing top-line results from oncology mechanism-of-action studies. The research examined a three-drug combination of Aramchol, Stivarga and Metformin in gastrointestinal (GI) tumor cells. According to the press release title, this combination significantly enhanced GI tumor cell killing in both in-vivo and in-vitro models. The 6-K mainly serves to formally provide this press release to the market as an exhibit for investors and regulators.
Galmed Pharmaceuticals (GLMD) reported that shareholders approved all proposals at its Annual General Meeting held on October 29, 2025. The proposals described in the proxy statement were approved with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.
This report on Form 6-K is incorporated by reference into Galmed’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163, 333-290399) and its Form F-3 (Registration Nos. 333-272722, 333-283241).
Galmed Pharmaceuticals reported that its Annual General Meeting of Shareholders was convened but adjourned for one day due to lack of quorum. The meeting will reconvene on October 29, 2025 at 4:00 p.m. Israel time at Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.
This report is incorporated by reference into the company’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and Form F-3 (Nos. 333-272722, 333-283241).
Galmed Pharmaceuticals Ltd. filed a Form S-8 to register an additional 500,000 ordinary shares, par value NIS 1.80 per share, for issuance under its 2013 Incentive Share Option Plan. This filing builds on prior S-8 registrations from 2015, 2018, and 2025 for the same plan, allowing the company to continue granting equity-based awards to eligible participants. The company incorporates by reference its latest Form 20-F, multiple Form 6-K reports, and the description of its ordinary shares, and includes legal and audit consents and a filing fee calculation as exhibits. The registration statement is signed by senior management, directors, and the company’s authorized U.S. representative.
Galmed Pharmaceuticals Ltd. reports it will hold its Annual General Meeting of Shareholders on October 28, 2025, at 4:00 p.m. (Israel time) at the offices of Meitar | Law Offices in Ramat Gan, Israel. The company has provided a Notice of the Annual General Meeting and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2. This report on Form 6-K is also incorporated by reference into Galmed’s existing Registration Statements on Form S-8 and Form F-3.